Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Multiple Myeloma

NCT02221479 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT02221479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02221479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Multiple Myeloma
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
July 31, 2015
Enrollment
14 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma